Limited Uptake of Biosimilars Despite Potential Cost Savings
Limited Uptake of Biosimilars Despite Potential Cost Savings: Patent Expiration and Value-Based Contracting to Drive Market Changes Summary: Biosimilars are drugs that reference a biologic and are concentrated in high-cost specialty drug markets such as oncology. Despite potential for cost savings in Medicare and other markets, uptake of biosimilars in the US has historically been […]